CLOSE
CLOSE
Wright Medical Group, Inc.
Search
Investor Relations
And information
HomeInvestor Relations › News Releases

News Releases

View printer-friendly version
<< Back
Wright Medical Group, Inc. Announces the Launch of New Foot and Ankle Products

ORTHOLOC™ 3Di Ankle Fracture System provides innovative product solution for treating ankle fractures

QUICKDRAW™ Knotless Soft Tissue Fixation System establishes strong foundation in the growing soft tissue fixation market

ARLINGTON, Tenn.--(BUSINESS WIRE)--Jan. 4, 2012-- Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company, today announced the launch of the ORTHOLOC 3Di Ankle Fracture System and the QUICKDRAW™ Knotless Soft Tissue Fixation System. Both products will be immediately available in the U.S. through Wright Medical’s specialized foot and ankle sales force. They will also be marketed in select countries outside the U.S. through Wright Medical’s direct and distributor-based sales organization.

“We are very pleased to launch the ORTHOLOC 3Di Ankle Fracture System, which further expands our foot and ankle product portfolio and provides surgeons with an innovative solution to treat a wide range of ankle fractures,” said Robert Palmisano, President and Chief Executive Officer. “In addition, the launch of the QUICKDRAW™ Knotless Soft Tissue Fixation System through our distribution agreement with ArthroCare® Corporation will establish a strong foundation for Wright Medical in the growing soft tissue fixation market.”

The ORTHOLOC 3Di Ankle Fracture System is a comprehensive single-tray ankle fracture solution designed to address a wide range of fracture types and classifications. Employing the highly versatile ORTHOLOC 3Di polyaxial locking technology, this system provides multiple anatomically-contoured plates and a comprehensive set of instrumentation to enable the surgeon to match the appropriate implant construct with the patient and fracture type and can decrease logistical complications in the operating room. Ankle fractures represent one of the most common injuries in the foot with approximately 170,000 ankle fractures treated surgically each year.¹

Based on ArthroCare’s market-leading Opus® knotless suturing technology, the QUICKDRAW™ Soft Tissue Fixation System provides a solution for a variety of soft tissue reattachment procedures of the foot and ankle, which number over 250,000 surgeries each year in the U.S.¹ The system is composed of the BELAY™ and MINI-BELAY™ Knotless Suture Anchors, RAPPEL-LINE™ Surgical Suture and instrumentation that is designed to simplify suture management and placement. When combined, these components can quickly and securely fixate ruptured or reattach tendons within the foot and ankle, including the challenging repair and reconstruction procedures of the Achilles tendon.

More information on Wright Medical’s foot and ankle products, including the ORTHOLOC 3Di Ankle Fracture System and the QUICKDRAW™ Knotless Soft Tissue Fixation System can be found at www.wmt.com/footandankle/.

About Wright Medical

Wright Medical Group, Inc. is a global orthopaedic medical device company and a leading provider of surgical solutions for the foot and ankle market. The Company specializes in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction. The Company has been in business for more than 60 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit the Company’s website at www.wmt.com.

1. “2011 US Markets for Orthopedic Extremity Devices,” published October 2010 by Millennium Research Group, Inc.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Such risks and uncertainties include the impact of Wright's settlement of the federal investigation into Wright's consulting arrangements with orthopaedic surgeons relating to its hip and knee products in the United States, including Wright's compliance with a Deferred Prosecution Agreement through September 2012 and a Corporate Integrity Agreement through September 2015, and those risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2010, under the heading, "Risk Factors" and in Item 1A of Part II of our 10-Qs filed during 2011). Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date.

Source: Wright Medical Group, Inc.

Wright Medical Group, Inc.
Investors & Media:
Julie D. Tracy, 901-290-5817
Sr. Vice President, Chief Communications Officer
julie.tracy@wmt.com